Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma

Academic Article
Publication Date:
2008
abstract:
Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.
Iris type:
1.1 Articolo in rivista
List of contributors:
Ferreri, Ajm; Dognini, Gp; Bairey, O; Szomor, A; Montalban, C; Horvath, B; Demeter, J; Uziel, L; Soffietti, R; Seymour, Jf; Ambrosetti, A; Willemze, R; Martelli, M; Rossi, G; Candoni, A; De Renzo, A; Doglioni, C; Zucca, E; Cavalli, F; Ponzoni, Maurilio
Authors of the University:
FERRERI ANDRES JOSE MARIA
PONZONI MAURILIO
Handle:
https://iris.unisr.it/handle/20.500.11768/16582
Published in:
BRITISH JOURNAL OF HAEMATOLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0